Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin Better Than Ticlopidine For Stroke Recurrence Prevention In Blacks

This article was originally published in The Tan Sheet

Executive Summary

Aspirin appears to be a "better treatment for aspirin-tolerant black patients with noncardioembolic ischemic stroke" than ticlopidine (Roche's Ticlid) for prevention of recurrent stroke, myocardial infarction and vascular death, according to a recent study

You may also be interested in...



NINDS study of aspirin v. ticlopidine in stroke prevention to begin patient accrual.

NINDS STUDY COMPARING ASPIRIN WITH TICLOPIDINE IN STROKE PREVENTION in African Americans is expected to begin patient accrual in early November. The study, comparing aspirin with ticlopidine (Roche/Syntex' Ticlid) for recurrent stroke prevention, will be conducted under the direction of researchers at The Rush-Presbyterian-St. Luke's Medical Center in Chicago. The five-year, $10.8 mil. study is funded by a grant from the National Institute of Neurological Disorders & Stroke.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

PS095569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel